Fragment-based screening (FBS) is a widely utilized strategy for the discovery of lead compounds. Especially in the development of drugs against unconventional targets such as protein-protein interactions (PPIs), FBS has proven to be a viable alternative to high-throughput screening (HTS). Leveraging advanced fragment-based drug design (FBDD) platform, Creative Biostructure provides FBS solutions for customers with hit identification needs, which involve various biophysical methods to determine the exact binding fragments.